{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:03:21Z","timestamp":1789707801272,"version":"4.0.1"},"reference-count":198,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union\u2014NextGenerationEU under the Italian University and Research (MUR) National Innovation Ecosystem","award":["ECS00000041\u2013VITALITY\u2013CUP E13C22001060006"],"award-info":[{"award-number":["ECS00000041\u2013VITALITY\u2013CUP E13C22001060006"]}]},{"name":"University of L\u2019Aquila","id":[{"id":"https:\/\/ror.org\/01j9p1r26","id-type":"ROR","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/01j9p1r26","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Glioblastoma multiforme (GBM) is an extremely aggressive and lethal brain tumor, characterized by marked molecular heterogeneity, the persistence of glioma stem cells (GSCs), and the limited permeability of the blood\u2013brain barrier (BBB), which collectively hinder therapeutic efficacy. To address these barriers, nucleic acid aptamers, short single-stranded oligonucleotides with high affinity and specificity for molecular targets, have emerged as a promising therapeutic platform. Early unmodified aptamers, such as AS1411 and U2, demonstrated target engagement but showed limited performance due to instability and rapid systemic clearance. Chemical modifications, including 2\u2032-fluoro substitutions and PEGylation, resulted in improved stability, specificity, and pharmacokinetic properties, enabling the development of innovative aptamer drug conjugates (ApDCs) for targeted delivery to GBM cells. In parallel, multivalent aptamer architectures, such as bispecific aptamer targeting entities (BATEs) and aptamer guided nanostructures, have been designed to enhance binding avidity, address tumor heterogeneity, and facilitate BBB transcytosis. More recently, computational strategies ranging from machine learning-guided sequence optimization to structure prediction and generative AI have accelerated the rational design of aptamers tailored to GBM specific challenges. This review examines these advances, the remaining pharmacological limitations, and the potential of computational tools to reshape the future of aptamer based GBM therapeutics.<\/jats:p>","DOI":"10.3390\/ijms27188231","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:58:59Z","timestamp":1789545539000},"page":"8231","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular Engineering of Aptamers for Glioblastoma Therapy: From Simple Antagonists to AI-Driven Approaches, a Narrative Review"],"prefix":"10.3390","volume":"27","author":[{"given":"Luana","family":"Di Leandro","sequence":"first","affiliation":[{"name":"Department of Life, Health and Environmental Sciences, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0882-0892","authenticated-orcid":false,"given":"Martina","family":"Colasante","sequence":"additional","affiliation":[{"name":"Department of Life, Health and Environmental Sciences, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Catanesi","sequence":"additional","affiliation":[{"name":"Department of Life, Health and Environmental Sciences, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giansanti","sequence":"additional","affiliation":[{"name":"Department of Life, Health and Environmental Sciences, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2737-7970","authenticated-orcid":false,"given":"Annamaria","family":"Cimini","sequence":"additional","affiliation":[{"name":"Department of Life, Health and Environmental Sciences, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"},{"name":"Sbarro Institute for Cancer Research and Molecular Medicine, Department of Biology, Temple University, Philadelphia, PA 19122, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3693-840X","authenticated-orcid":false,"given":"Michele","family":"D\u2019Angelo","sequence":"additional","affiliation":[{"name":"Department of Life, Health and Environmental Sciences, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"},{"name":"Sbarro Institute for Cancer Research and Molecular Medicine, Department of Biology, Temple University, Philadelphia, PA 19122, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7005-3218","authenticated-orcid":false,"given":"Vanessa","family":"Castelli","sequence":"additional","affiliation":[{"name":"Department of Life, Health and Environmental Sciences, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Savino","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Magna Graecia University, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Ippoliti","sequence":"additional","affiliation":[{"name":"Department of Life, Health and Environmental Sciences, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"ref_1","first-page":"381","article-title":"Brain and Other Central Nervous System Tumor Statistics, 2021","volume":"71","author":"Miller","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"100715","article-title":"National Brain Tumour Registry of China (NBTRC) Statistical Report of Primary Brain Tumours Diagnosed in China in Years 2019\u20132020","volume":"34","author":"Xiao","year":"2023","journal-title":"Lancet Reg. Health West. Pac."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016\u20132020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro-Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lan, Z., Li, X., and Zhang, X. (2024). Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25053040"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00221-025-07018-7","article-title":"Glioblastoma Induced Blood-Brain Barrier Dysfunction via a Paracrine Mechanism That Increases Claudin-1 Expression","volume":"243","author":"Schweiger","year":"2025","journal-title":"Exp. Brain Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the Blood-Brain Barrier Really Disrupted in All Glioblastomas? A Critical Assessment of Existing Clinical Data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro-Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"D\u2019Alessio, A., Proietti, G., Sica, G., and Scicchitano, B.M. (2019). Pathological and Molecular Features of Glioblastoma and Its Peritumoral Tissue. Cancers, 11.","DOI":"10.3390\/cancers11040469"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/cac2.12361","article-title":"An Update on the Molecular Biology of Glioblastoma, with Clinical Implications and Progress in Its Treatment","volume":"42","author":"Verdugo","year":"2022","journal-title":"Cancer Commun."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Biserova, K., Jakovlevs, A., Uljanovs, R., and Strumfa, I. (2021). Cancer Stem Cells: Significance in Origin, Pathogenesis and Treatment of Glioblastoma. Cells, 10.","DOI":"10.3390\/cells10030621"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trecan.2022.09.005","article-title":"Challenges in Glioblastoma Research: Focus on the Tumor Microenvironment","volume":"9","author":"Bikfalvi","year":"2023","journal-title":"Trends Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-59038-3_1","article-title":"Targeting Glioblastoma Tumor Microenvironment","volume":"1296","author":"Butler","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/346818a0","article-title":"In Vitro Selection of RNA Molecules That Bind Specific Ligands","volume":"346","author":"Ellington","year":"1990","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Xu, Y., Jiang, X., Zhou, Y., Ma, M., Wang, M., and Ying, B. (2021). Systematic Evolution of Ligands by Exponential Enrichment Technologies and Aptamer-Based Applications: Recent Progress and Challenges in Precision Medicine of Infectious Diseases. Front. Bioeng. Biotechnol., 9.","DOI":"10.3389\/fbioe.2021.704077"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"32231","DOI":"10.1021\/acsomega.3c04345","article-title":"Recent Advancements of Aptamers in Cancer Therapy","volume":"8","author":"Venkatesan","year":"2023","journal-title":"ACS Omega"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ni, S., Yao, H., Wang, L., Lu, J., Jiang, F., Lu, A., and Zhang, G. (2017). Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18081683"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/1061186X.2024.2373306","article-title":"Aptamers: Ushering in New Hopes in Targeted Glioblastoma Therapy","volume":"32","author":"Chatterjee","year":"2024","journal-title":"J. Drug Target."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Amero, P., Khatua, S., Rodriguez-Aguayo, C., and Lopez-Berestein, G. (2020). Aptamers: Novel Therapeutics and Potential Role in Neuro-Oncology. Cancers, 12.","DOI":"10.3390\/cancers12102889"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1021\/cn100114k","article-title":"In Vitro Selection of DNA Aptamers to Glioblastoma Multiforme","volume":"2","author":"Bayrac","year":"2011","journal-title":"ACS Chem. Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Adachi, T., and Nakamura, Y. (2019). Aptamers: A Review of Their Chemical Properties and Modifications for Therapeutic Application. Molecules, 24.","DOI":"10.3390\/molecules24234229"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2147\/IJN.S237544","article-title":"Aptamers as Versatile Ligands for Biomedical and Pharmaceutical Applications","volume":"15","author":"Guan","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13046-022-02349-7","article-title":"Emerging Therapies for Glioblastoma: Current State and Future Directions","volume":"41","author":"Rong","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"105780","DOI":"10.1016\/j.phrs.2021.105780","article-title":"Glioblastoma Multiforme (GBM): An Overview of Current Therapies and Mechanisms of Resistance","volume":"171","author":"Wu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_23","first-page":"1","article-title":"Overcoming the Blood-Brain Tumor Barrier for Effective Glioblastoma Treatment","volume":"19","author":"Wesseling","year":"2015","journal-title":"Drug Resist. Updates"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1038\/s41467-023-40579-1","article-title":"Optical Blood-Brain-Tumor Barrier Modulation Expands Therapeutic Options for Glioblastoma Treatment","volume":"14","author":"Cai","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11060-024-04760-w","article-title":"Blood-Tumor Barrier in Focus\u2014Investigation of Glioblastoma-Induced Effects on the Blood-Brain Barrier","volume":"170","author":"Peindl","year":"2024","journal-title":"J. Neurooncol."},{"key":"ref_26","unstructured":"Levin, A.A., Yu, R.Z., and Geary, R.S. (2007). Basic Principles of the Pharmacokinetics of Antisense Oligonucleotide Drugs. Antisense Drug Technology: Principles, Strategies, and Applications, CRC Press. [2nd ed.]."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2018.10.008","article-title":"Pharmacokinetics, Pharmacodynamics and Safety of Aptamers","volume":"134","author":"Kovacevic","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.apsb.2023.01.017","article-title":"Recent Progress of Aptamer\u2013drug Conjugates in Cancer Therapy","volume":"13","author":"He","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"124998","DOI":"10.1016\/j.talanta.2023.124998","article-title":"Recent Progress of SELEX Methods for Screening Nucleic Acid Aptamers","volume":"266","author":"Zhu","year":"2024","journal-title":"Talanta"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2018.08.005","article-title":"Aptamer-Based Targeted Therapy","volume":"134","author":"Zhu","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Van den Avont, A., and Sharma-Walia, N. (2023). Anti-Nucleolin Aptamer AS1411: An Advancing Therapeutic. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1217769"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.omtn.2018.01.001","article-title":"Effects of Aptamer to U87-EGFRvIII Cells on the Proliferation, Radiosensitivity, and Radiotherapy of Glioblastoma Cells","volume":"10","author":"Zhang","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Wu, X., Liang, H., Tan, Y., Yuan, C., Li, S., Li, X., Li, G., Shi, Y., and Zhang, X. (2014). Cell-SELEX Aptamer for Highly Specific Radionuclide Molecular Imaging of Glioblastoma In Vivo. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090752"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"37570","DOI":"10.18632\/oncotarget.6066","article-title":"Aptamer Targeting EGFRvIII Mutant Hampers Its Constitutive Autophosphorylation and Affects Migration, Invasion and Proliferation of Glioblastoma Cells","volume":"6","author":"Camorani","year":"2015","journal-title":"Oncotarget"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/mt.2013.300","article-title":"Inhibition of Receptor Signaling and of Glioblastoma-Derived Tumor Growth by a Novel PDGFR\u03b2 Aptamer","volume":"22","author":"Camorani","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.omtn.2019.08.015","article-title":"The Discovery of RNA Aptamers That Selectively Bind Glioblastoma Stem Cells","volume":"18","author":"Affinito","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.omtn.2020.02.005","article-title":"Targeting Ephrin Receptor Tyrosine Kinase A2 with a Selective Aptamer for Glioblastoma Stem Cells","volume":"20","author":"Affinito","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1021\/acs.jcim.5c00295","article-title":"Targeting Glioblastoma Stem Cells via EphA2: Structural Insights into the RNA Aptamer A40s for Precision Therapy","volume":"65","author":"Diakogiannaki","year":"2025","journal-title":"J. Chem. Inf. Model."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/nat.2015.0580","article-title":"Identification of an Interfering Ligand Aptamer for EphB2\/3 Receptors","volume":"26","author":"Amero","year":"2016","journal-title":"Nucleic Acid. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kang, D., Wang, J., Zhang, W., Song, Y., Li, X., Zou, Y., Zhu, M., Zhu, Z., Chen, F., and Yang, C.J. (2012). Selection of DNA Aptamers against Glioblastoma Cells with High Affinity and Specificity. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0042731"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Li, N., Nguyen, H.H., Byrom, M., and Ellington, A.D. (2011). Inhibition of Cell Proliferation by an Anti-EGFR Aptamer. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020299"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1515\/BC.2009.022","article-title":"Aptamers Selected against the Unglycosylated EGFRvIII Ectodomain and Delivered Intracellularly Reduce Membrane-Bound EGFRvIII and Induce Apoptosis","volume":"390","author":"Liu","year":"2009","journal-title":"Biol. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/aps.2013.137","article-title":"DNA Aptamers That Target Human Glioblastoma Multiforme Cells Overexpressing Epidermal Growth Factor Receptor Variant III In Vitro","volume":"34","author":"Tan","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3892\/br.2014.276","article-title":"A U87-EGFRvIII Cell-Specific Aptamer Mediates Small Interfering RNA Delivery","volume":"2","author":"Zhang","year":"2014","journal-title":"Biomed. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Liu, X., Chen, Y., Geng, D., Li, H., Jiang, T., Luo, Z., Wang, J., Pang, Z., and Zhang, J. (2022). Aptamer-Modified Erythrocyte Membrane-Coated pH-Sensitive Nanoparticles for c-Met-Targeted Therapy of Glioblastoma Multiforme. Membranes, 12.","DOI":"10.3390\/membranes12080744"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"13131","DOI":"10.1039\/C4CC06016D","article-title":"A DNA Aptamer to C-Met Inhibits Cancer Cell Migration","volume":"50","author":"Ueki","year":"2014","journal-title":"Chem. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1039\/C6OB02577C","article-title":"Chemical Modification Improves the Stability of the DNA Aptamer GBI-10 and Its Affinity towards Tenascin-C","volume":"15","author":"Li","year":"2017","journal-title":"Org. Biomol. Chem."},{"key":"ref_48","first-page":"668","article-title":"Tumor Targeting by an Aptamer","volume":"47","author":"Hicke","year":"2006","journal-title":"J. Nucl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1038\/mt.2012.163","article-title":"Targeting Axl with an High-Affinity Inhibitory Aptamer","volume":"20","author":"Cerchia","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1016\/j.biomaterials.2012.05.020","article-title":"Whole-Cell SELEX Aptamer-Functionalised Poly(Ethyleneglycol)-Poly(\u03b5-Caprolactone) Nanoparticles for Enhanced Targeted Glioblastoma Therapy","volume":"33","author":"Gao","year":"2012","journal-title":"Biomaterials"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1038\/s41467-024-48416-9","article-title":"L-RNA Aptamer-Based CXCL12 Inhibition Combined with Radiotherapy in Newly-Diagnosed Glioblastoma: Dose Escalation of the Phase I\/II GLORIA Trial","volume":"15","author":"Giordano","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood-2013-03-493924","article-title":"The Spiegelmer NOX-A12, a Novel CXCL12 Inhibitor, Interferes with Chronic Lymphocytic Leukemia Cell Motility and Causes Chemosensitization","volume":"123","author":"Hoellenriegel","year":"2014","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1016\/j.ejca.2009.08.004","article-title":"Tumour Control by Whole Brain Irradiation of Anti-VEGF-Treated Mice Bearing Intracerebral Glioma","volume":"45","author":"Verhoeff","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Bege, M., Ghanem Kattoub, R., and Borb\u00e1s, A. (2025). The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in Therapy. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17030394"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.omtn.2018.11.012","article-title":"An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR\u03b1 Induces Anti-Tumor Effects through STAT3 and P53 in Glioblastoma","volume":"14","author":"Yoon","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Wang, T., Philippovich, S., Mao, J., and Veedu, R.N. (2019). Efficient Epidermal Growth Factor Receptor Targeting Oligonucleotide as a Potential Molecule for Targeted Cancer Therapy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194700"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"39525","DOI":"10.1021\/acsami.9b13829","article-title":"Enhanced Efficacy of Temozolomide Loaded by a Tetrahedral Framework DNA Nanoparticle in the Therapy for Glioblastoma","volume":"11","author":"Fu","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1021\/acs.bioconjchem.5c00137","article-title":"Transferrin Receptor-Targeted Aptamer\u2013Drug Conjugate Overcomes Blood\u2013Brain Barrier for Potent Glioblastoma Therapy","volume":"36","author":"Zhao","year":"2025","journal-title":"Bioconjug. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"518","DOI":"10.7150\/thno.21194","article-title":"A Transferrin-Conjugated Hollow Nanoplatform for Redox-Controlled and Targeted Chemotherapy of Tumor with Reduced Inflammatory Reactions","volume":"8","author":"Zhou","year":"2018","journal-title":"Theranostics"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Zhang, N., Bing, T., Shen, L., Feng, L., Liu, X., and Shangguan, D. (2021). A DNA Aptameric Ligand of Human Transferrin Receptor Generated by Cell-SELEX. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168923"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"102061","DOI":"10.1016\/j.nano.2019.102061","article-title":"Targeted and Effective Glioblastoma Therapy via Aptamer-Modified Tetrahedral Framework Nucleic Acid-Paclitaxel Nanoconjugates That Can Pass the Blood Brain Barrier","volume":"21","author":"Shi","year":"2019","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.omtn.2022.01.008","article-title":"Cancer Immunomodulation Using Bispecific Aptamers","volume":"27","author":"Thomas","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1021\/acschemneuro.6b00369","article-title":"Development of a Bifunctional Aptamer Targeting the Transferrin Receptor and Epithelial Cell Adhesion Molecule (EpCAM) for the Treatment of Brain Cancer Metastases","volume":"8","author":"Macdonald","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.1002\/smll.201601249","article-title":"Amino Acid Metabolism Abnormity and Microenvironment Variation Mediated Targeting and Controlled Glioma Chemotherapy","volume":"12","author":"An","year":"2016","journal-title":"Small"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"9102","DOI":"10.1021\/acs.jpcb.8b06802","article-title":"Probing ATP\/ATP-Aptamer or ATP-Aptamer Mutant Complexes by Microscale Thermophoresis and Molecular Dynamics Simulations: Discovery of an ATP-Aptamer Sequence of Superior Binding Properties","volume":"122","author":"Biniuri","year":"2018","journal-title":"J. Phys. Chem. B"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"8070","DOI":"10.1021\/acs.analchem.8b05941","article-title":"Evolution of Nucleic Acid Aptamers Capable of Specifically Targeting Glioma Stem Cells via Cell-SELEX","volume":"91","author":"Wu","year":"2019","journal-title":"Anal. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"9306","DOI":"10.1021\/acsami.0c11878","article-title":"Aptamer Generated by Cell-SELEX for Specific Targeting of Human Glioma Cells","volume":"13","author":"Lin","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"8153","DOI":"10.1021\/acsnano.2c11675","article-title":"Aptamer Nanoconstructs Crossing Human Blood\u2013Brain Barrier Discovered via Microphysiological System-Based SELEX Technology","volume":"17","author":"Choi","year":"2023","journal-title":"ACS Nano"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.omtn.2019.05.006","article-title":"RNA Aptamers Targeting Integrin A5\u03b21 as Probes for Cyto- and Histofluorescence in Glioblastoma","volume":"17","author":"Fechter","year":"2019","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Peng, Y., Wang, Y., Zhou, C., Mei, W., and Zeng, C. (2022). PI3K\/Akt\/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.819128"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Esposito, C.L., Nuzzo, S., Ibba, M.L., Ricci-Vitiani, L., Pallini, R., Condorelli, G., Catuogno, S., and de Franciscis, V. (2020). Combined Targeting of Glioblastoma Stem-Like Cells by Neutralizing RNA-Bio-Drugs for STAT3. Cancers, 12.","DOI":"10.3390\/cancers12061434"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Nuzzo, S., Brancato, V., Affinito, A., Salvatore, M., Cavaliere, C., and Condorelli, G. (2020). The Role of RNA and DNA Aptamers in Glioblastoma Diagnosis and Therapy: A Systematic Review of the Literature. Cancers, 12.","DOI":"10.3390\/cancers12082173"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.omtn.2022.09.008","article-title":"Development of a Novel PROTAC Using the Nucleic Acid Aptamer as a Targeting Ligand for Tumor Selective Degradation of Nucleolin","volume":"30","author":"Zhang","year":"2022","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1016\/j.xphs.2019.08.017","article-title":"AS1411 Aptamer\/Hyaluronic Acid-Bifunctionalized Microemulsion Co-Loading Shikonin and Docetaxel for Enhanced Antiglioma Therapy","volume":"108","author":"Wang","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1021\/mp300686g","article-title":"Nucleolin Targeting AS1411 Modified Protein Nanoparticle for Antitumor Drugs Delivery","volume":"10","author":"Wu","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-07-5723","article-title":"The Nucleolin Targeting Aptamer AS1411 Destabilizes Bcl-2 Messenger RNA in Human Breast Cancer Cells","volume":"68","author":"Soundararajan","year":"2008","journal-title":"Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Iturriaga-Goyon, E., Vivanco-Rojas, O., Maga\u00f1a-Guerrero, F.S., Buentello-Volante, B., Castro-Salas, I., Aguayo-Flores, J.E., Gracia-Mora, I., Rivera-Huerta, M., S\u00e1nchez-Bart\u00e9s, F., and Garfias, Y. (2021). AS1411 Nucleolin-Specific Binding Aptamers Reduce Pathological Angiogenesis through Inhibition of Nucleolin Phosphorylation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222313150"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.bbagen.2016.12.015","article-title":"G-Quadruplex Oligonucleotide AS1411 as a Cancer-Targeting Agent: Uses and Mechanisms","volume":"1861","author":"Bates","year":"2017","journal-title":"Biochim. Biophys. Acta (BBA) -Gen. Subj."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ijbiomac.2019.11.118","article-title":"Therapeutic Applications of AS1411 Aptamer, an Update Review","volume":"155","author":"Bayat","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Bie, L., Wang, Y., Jiang, F., Xiao, Z., Zhang, L., and Wang, J. (2022). Insights into the Binding Mode of AS1411 Aptamer to Nucleolin. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.1025313"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"20556","DOI":"10.1074\/jbc.273.32.20556","article-title":"2\u2032-Fluoropyrimidine RNA-Based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165): Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain","volume":"273","author":"Ruckman","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/nar\/27.6.1561","article-title":"Efficient Synthesis of Nucleic Acids Heavily Modified with Non-Canonical Ribose 2\u2032-Groups Using a Mutant T7 RNA Polymerase (RNAP)","volume":"27","author":"Padilla","year":"1999","journal-title":"Nucleic Acids Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1002\/slct.201700359","article-title":"Systematic Optimization and Modification of a DNA Aptamer with 2\u2032-O-Methyl RNA Analogues","volume":"2","author":"Maio","year":"2017","journal-title":"ChemistrySelect"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1039\/D6CB00062B","article-title":"Stability Modification of Therapeutic Aptamers: From Biostability Bottlenecks to Nuclease-Resistant Construct Design","volume":"7","author":"Pan","year":"2026","journal-title":"RSC Chem. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bpc.2009.09.011","article-title":"Conformation and Thermostability of Oligonucleotide d(GGTTGGTGTGGTTGG) Containing Thiophosphoryl Internucleotide Bonds at Different Positions","volume":"146","author":"Zaitseva","year":"2010","journal-title":"Biophys. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.aca.2013.12.023","article-title":"Locked Nucleic Acid\/DNA Chimeric Aptamer Probe for Tumor Diagnosis with Improved Serum Stability and Extended Imaging Window In Vivo","volume":"812","author":"Shi","year":"2014","journal-title":"Anal. Chim. Acta"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5757","DOI":"10.1093\/nar\/gkh862","article-title":"Application of Locked Nucleic Acids to Improve Aptamer In Vivo Stability and Targeting Function","volume":"32","author":"Schmidt","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.xphs.2015.11.015","article-title":"PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs","volume":"105","author":"Turecek","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"ter Linden, E., Abels, E.R., van Solinge, T.S., Neefjes, J., and Broekman, M.L.D. (2024). Overcoming Barriers in Glioblastoma\u2014Advances in Drug Delivery Strategies. Cells, 13.","DOI":"10.3390\/cells13120998"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Pulgar, V.M. (2018). Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges. Front. Neurosci., 12.","DOI":"10.3389\/fnins.2018.01019"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Li, Y., Liu, R., and Zhao, Z. (2025). Targeting Brain Drug Delivery with Macromolecules Through Receptor-Mediated Transcytosis. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17010109"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Ghorai, S.M., Deep, A., Magoo, D., Gupta, C., and Gupta, N. (2023). Cell-Penetrating and Targeted Peptides Delivery Systems as Potential Pharmaceutical Carriers for Enhanced Delivery across the Blood-Brain Barrier (BBB). Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15071999"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/bjp.2008.260","article-title":"Antitumour Activity of ANG1005, a Conjugate between Paclitaxel and the New Brain Delivery Vector Angiopep-2","volume":"155","author":"Demeule","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2019.05.022","article-title":"Robotic Assisted Generation of 2\u2032-Deoxy-2\u2032-Fluoro-Modifed RNA Aptamers\u2014High Performance Enabling Strategies in Aptamer Selection","volume":"161","author":"Breuers","year":"2019","journal-title":"Methods"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Odeh, F., Nsairat, H., Alshaer, W., Ismail, M.A., Esawi, E., Qaqish, B., Bawab, A.A., and Ismail, S.I. (2019). Aptamers Chemistry: Chemical Modifications and Conjugation Strategies. Molecules, 25.","DOI":"10.3390\/molecules25010003"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1016\/j.bmcl.2009.10.039","article-title":"Aptamers as a Model for Functional Evaluation of LNA and 2\u2032-Amino LNA","volume":"19","author":"Hernandez","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.chembiol.2019.02.001","article-title":"Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers","volume":"26","author":"Moreno","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS Nano"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.drudis.2014.09.004","article-title":"Turning Mirror-Image Oligonucleotides into Drugs: The Evolution of Spiegelmer\u00ae Therapeutics","volume":"20","author":"Vater","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of Monoclonal Antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.trecan.2025.08.014","article-title":"CAR T Cell Persistence in Cancer","volume":"11","author":"Mueller","year":"2025","journal-title":"Trends Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12967-024-06052-3","article-title":"From Ex Vivo to In Vivo Chimeric Antigen T Cells Manufacturing: New Horizons for CAR T-Cell Based Therapy","volume":"23","author":"Pinto","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"106614","DOI":"10.1016\/j.jddst.2025.106614","article-title":"Designing Multivalent Aptamers: Recent Advancements in Diagnostic and Therapeutic Approaches for Cancer Treatment","volume":"105","author":"Moradi","year":"2025","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12935-024-03295-4","article-title":"Aptamers as an Approach to Targeted Cancer Therapy","volume":"24","author":"Mahmoudian","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"125902","DOI":"10.1016\/j.ijpharm.2025.125902","article-title":"Aptamer-Drug Conjugates (ApDCs): Transformative Approaches in Targeted Cancer Therapy and Precision Oncology","volume":"681","author":"Zahedi","year":"2025","journal-title":"Int. J. Pharm."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Desgraves, J.F., Mendez Valdez, M.J., Chandar, J., Gurses, M.E., Henderson, L., Castro, J.R., Seetheram, D., Ivan, M.E., Komotar, R.J., and Shah, A.H. (2024). Antisense Oligonucleotides for Rapid Translation of Gene Therapy in Glioblastoma. Cancers, 16.","DOI":"10.3390\/cancers16101944"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"eabb3945","DOI":"10.1126\/scitranslmed.abb3945","article-title":"A First-in-Human Phase 0 Clinical Study of RNA Interference-Based Spherical Nucleic Acids in Patients with Recurrent Glioblastoma","volume":"13","author":"Kumthekar","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2016.12.003","article-title":"Intracerebral Injection of CpG Oligonucleotide for Patients with De Novo Glioblastoma\u2014A Phase II Multicentric, Randomised Study","volume":"73","author":"Ursu","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2217\/fon-2023-0702","article-title":"Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients","volume":"20","author":"Lee","year":"2024","journal-title":"Future Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1158\/1078-0432.CCR-20-3805","article-title":"Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma","volume":"27","author":"Andrews","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"102485","DOI":"10.1016\/j.tranon.2025.102485","article-title":"Aptamer-Mediated Delivery of Therapeutic Oligonucleotides in Glioblastoma","volume":"60","author":"Castellani","year":"2025","journal-title":"Transl. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.omtn.2017.12.021","article-title":"STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma","volume":"10","author":"Esposito","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"122479","DOI":"10.1016\/j.biomaterials.2024.122479","article-title":"Gint4.T-siHDGF Chimera-Capped Mesoporous Silica Nanoparticles Encapsulating Temozolomide for Synergistic Glioblastoma Therapy","volume":"306","author":"Fei","year":"2024","journal-title":"Biomaterials"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1080\/10717544.2018.1494225","article-title":"Dual-Modified Cationic Liposomes Loaded with Paclitaxel and Survivin siRNA for Targeted Imaging and Therapy of Cancer Stem Cells in Brain Glioma","volume":"25","author":"Sun","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2012.11.032","article-title":"RNA Aptamers Targeting Cancer Stem Cell Marker CD133","volume":"330","author":"Shigdar","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2400837","DOI":"10.1002\/adfm.202400837","article-title":"Target Reprogramming the 3\u2032 UTR of Tumor-Suppressor Genes by a siRNA Composite Nanoparticle for Glioblastoma Therapy","volume":"34","author":"Gu","year":"2024","journal-title":"Adv. Funct. Mater."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"122788","DOI":"10.1016\/j.lfs.2024.122788","article-title":"Survivin (BIRC5): Implications in Cancer Therapy","volume":"350","author":"Siragusa","year":"2024","journal-title":"Life Sci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e0571","DOI":"10.1097\/MD.0000000000010571","article-title":"Prognostic Role of Survivin in Patients with Glioma","volume":"97","author":"Zhang","year":"2018","journal-title":"Medicine"},{"key":"ref_119","first-page":"359","article-title":"Survivin Is a Prognostic Indicator in Glioblastoma and May Be a Target of microRNA-218","volume":"18","author":"Tong","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Elliott, W.J., Gurramkonda, N., Guda, M.R., Tsung, A.J., and Velpula, K.K. (2025). Survivin Interference and SurVaxM as an Adjunct Therapy for Glioblastoma Multiforme. Cells, 14.","DOI":"10.3390\/cells14100755"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Wang, H., Tan, Y., Jia, H., Liu, D., and Liu, R. (2022). Posaconazole Inhibits the Stemness of Cancer Stem-like Cells by Inducing Autophagy and Suppressing the Wnt\/\u03b2-Catenin\/Survivin Signaling Pathway in Glioblastoma. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.905082"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e2420630","DOI":"10.1002\/adma.202420630","article-title":"Intranasal and Intravenous Sequential Administration of Survivin Peptide-CpG Nanovaccines Elicits Potent Immunity Toward Glioblastoma","volume":"37","author":"Shi","year":"2025","journal-title":"Adv. Mater."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2147\/IJN.S295598","article-title":"Self-Assembled DNA Nanostructure as a Carrier for Targeted siRNA Delivery in Glioma Cells","volume":"16","author":"Zhou","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.18632\/oncotarget.28039","article-title":"Role of microRNAs in Glioblastoma","volume":"12","author":"Chen","year":"2021","journal-title":"Oncotarget"},{"key":"ref_125","first-page":"7639084","article-title":"MicroRNA in Glioblastoma: An Overview","volume":"2017","author":"Banelli","year":"2017","journal-title":"Int. J. Genom."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/cam4.775","article-title":"MicroRNAs in Glioblastoma Multiforme Pathogenesis and Therapeutics","volume":"5","author":"Shea","year":"2016","journal-title":"Cancer Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"100193","DOI":"10.1016\/j.crphar.2024.100193","article-title":"The Potential of miRNA-Based Approaches in Glioblastoma: An Update in Current Advances and Future Perspectives","volume":"7","author":"Espinosa","year":"2024","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Makowska, M., Smolarz, B., and Romanowicz, H. (2023). microRNAs (miRNAs) in Glioblastoma Multiforme (GBM)-Recent Literature Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043521"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Epistolio, S., Spina, P., Zaed, I., Cardia, A., Marchi, F., and Frattini, M. (2025). The Clinical Role of miRNAs in the Development and Treatment of Glioblastoma. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202502.0177.v1"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"di Leandro, L., Giansanti, F., Mei, S., Ponziani, S., Colasante, M., Ardini, M., Angelucci, F., Pitari, G., d\u2019Angelo, M., and Cimini, A. (2021). Aptamer-Driven Toxin Gene Delivery in U87 Model Glioblastoma Cells. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.588306"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"9859","DOI":"10.1007\/s12274-023-5742-7","article-title":"Aptamer-Functionalized Nanoplatforms Overcoming Temozolomide Resistance in Synergistic Chemo\/Photothermal Therapy through Alleviating Tumor Hypoxia","volume":"16","author":"Zeng","year":"2023","journal-title":"Nano Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s11095-021-03050-8","article-title":"Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma\u2014In Vitro Evaluation in Glioblastoma Stem Cells","volume":"38","author":"Smiley","year":"2021","journal-title":"Pharm. Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1021\/acs.langmuir.1c02500","article-title":"Membrane-Decorated Exosomes for Combination Drug Delivery and Improved Glioma Therapy","volume":"38","author":"Liang","year":"2022","journal-title":"Langmuir"},{"key":"ref_134","first-page":"28","article-title":"Rising to the Challenge: Recent Aptamer-Conjugate Success in Treating Glioblastoma","volume":"6","author":"Giles","year":"2022","journal-title":"Aptamers"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4155\/tde-2021-0086","article-title":"Novel Therapeutics and Drug-Delivery Approaches in the Modulation of Glioblastoma Stem Cell Resistance","volume":"13","author":"Smiley","year":"2022","journal-title":"Ther. Deliv."},{"key":"ref_136","first-page":"9628289","article-title":"Association of Glioblastoma Multiforme Stem Cell Characteristics, Differentiation, and Microglia Marker Genes with Patient Survival","volume":"2018","author":"Balz","year":"2018","journal-title":"Stem Cells Int."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of Human Brain Tumour Initiating Cells","volume":"432","author":"Singh","year":"2004","journal-title":"Nature"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1016\/j.biomaterials.2011.07.004","article-title":"Aptamer-Functionalized PEG\u2013PLGA Nanoparticles for Enhanced Anti-Glioma Drug Delivery","volume":"32","author":"Guo","year":"2011","journal-title":"Biomaterials"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"109121","DOI":"10.1016\/j.biopha.2019.109121","article-title":"HPA Aptamer Functionalized Paclitaxel-Loaded PLGA Nanoparticles for Enhanced Anticancer Therapy through Targeted Effects and Microenvironment Modulation","volume":"117","author":"Duan","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.2147\/IJN.S238206","article-title":"Aptamer-Conjugated Gold Nanoparticles Targeting Epidermal Growth Factor Receptor Variant III for the Treatment of Glioblastoma","volume":"15","author":"Peng","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Yalamarty, S.S.K., Filipczak, N., Li, X., Subhan, M.A., Parveen, F., Ataide, J.A., Rajmalani, B.A., and Torchilin, V.P. (2023). Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM). Cancers, 15.","DOI":"10.3390\/cancers15072116"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"S\u00f8rensen, B.S., and Horsman, M.R. (2020). Tumor Hypoxia: Impact on Radiation Therapy and Molecular Pathways. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00562"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10555-014-9493-5","article-title":"Emerging Roles of Radioresistance in Prostate Cancer Metastasis and Radiation Therapy","volume":"33","author":"Chang","year":"2014","journal-title":"Cancer Metastasis Rev."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"112330","DOI":"10.1016\/j.colsurfb.2022.112330","article-title":"GMT8 Aptamer Conjugated PEGylated Ag@Au Core-Shell Nanoparticles as a Novel Radiosensitizer for Targeted Radiotherapy of Glioma","volume":"211","author":"Li","year":"2022","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"114328","DOI":"10.1016\/j.colsurfb.2024.114328","article-title":"Dual-Targeted TfRA4-DNA1-Ag@AuNPs: An Innovative Radiosensitizer for Enhancing Radiotherapy in Glioblastoma Multiforme","volume":"245","author":"Kan","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"145102","DOI":"10.1088\/1361-6528\/abd20a","article-title":"Increasing the Accumulation of Aptamer AS1411 and Verapamil Conjugated Silver Nanoparticles in Tumor Cells to Enhance the Radiosensitivity of Glioma","volume":"32","author":"Zhao","year":"2021","journal-title":"Nanotechnology"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1039\/D1TB02098F","article-title":"Aptamers: An Emerging Navigation Tool of Therapeutic Agents for Targeted Cancer Therapy","volume":"10","author":"Yang","year":"2022","journal-title":"J. Mater. Chem. B"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Giles, B., Nakhjavani, M., Wiesa, A., Knight, T., Shigdar, S., and Samarasinghe, R.M. (2023). Unravelling the Glioblastoma Tumour Microenvironment: Can Aptamer Targeted Delivery Become Successful in Treating Brain Cancers?. Cancers, 15.","DOI":"10.20944\/preprints202308.1054.v1"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41416-020-01136-5","article-title":"Tumour Treating Fields Therapy for Glioblastoma: Current Advances and Future Directions","volume":"124","author":"Rominiyi","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.2174\/0118715206364677250401190214","article-title":"Recent Approaches on Oncolytic Viruses, Aptamers, TTFields and Personalized Treatment Used for the Management of Glioblastoma: A Comprehensive Review","volume":"25","author":"Singh","year":"2025","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Liu, R.N., Huang, J.H., Qi, X., Pan, Y., Wu, E., and Nizamutdinov, D. (2025). Tumor Treating Fields and Combination Therapy in Management of Brain Oncology. Cancers, 17.","DOI":"10.3390\/cancers17071211"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Wang, B., Kobeissy, F., Golpich, M., Cai, G., Li, X., Abedi, R., Haskins, W., Tan, W., Benner, S.A., and Wang, K.K.W. (2024). Aptamer Technologies in Neuroscience, Neuro-Diagnostics and Neuro-Medicine Development. Molecules, 29.","DOI":"10.3390\/molecules29051124"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00109-018-1669-y","article-title":"Bispecific Therapeutic Aptamers for Targeted Therapy of Cancer: A Review on Cellular Perspective","volume":"96","author":"Vandghanooni","year":"2018","journal-title":"J. Mol. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/smll.201002292","article-title":"Targeted Cell-Cell Interactions by DNA Nanoscaffold-Templated Multivalent Bispecific Aptamers","volume":"7","author":"Liu","year":"2011","journal-title":"Small"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3892\/ol.2025.15071","article-title":"Application of Multivalent Aptamers in Tumor Diagnosis, Analysis and Therapy (Review)","volume":"30","author":"Zeng","year":"2025","journal-title":"Oncol. Lett."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Wang, Z., Yang, X., Lee, N.Z., and Cao, X. (2022). Multivalent Aptamer Approach: Designs, Strategies, and Applications. Micromachines, 13.","DOI":"10.3390\/mi13030436"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Xia, B., and Zhu, Q. (2025). Aptamer\u2013ODN Chimeras: Enabling Cell-Specific ODN Targeting Therapy. Cells, 14.","DOI":"10.3390\/cells14100697"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"nwaa202","DOI":"10.1093\/nsr\/nwaa202","article-title":"Engineering G-Quadruplex Aptamer to Modulate Its Binding Specificity","volume":"8","author":"Li","year":"2020","journal-title":"Natl. Sci. Rev."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Abdu, A.M.A., Liu, Y., Abduljabbar, R., Man, Y., Chen, Q., and Liu, Z. (2025). Aptamers Targeting Immune Checkpoints for Tumor Immunotherapy. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17080948"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s12276-023-01136-4","article-title":"4-1BB Immunotherapy: Advances and Hurdles","volume":"56","author":"Singh","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","article-title":"Immunotherapy Targeting 4-1BB: Mechanistic Rationale, Clinical Results, and Future Strategies","volume":"131","author":"Chester","year":"2018","journal-title":"Blood"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/1535-7163.MCT-11-0677","article-title":"Immunotherapy of Cancer with 4-1BB","volume":"11","author":"Vinay","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1038\/s41467-021-27613-w","article-title":"CD137 (4-1BB) Costimulation of CD8+ T Cells Is More Potent When Provided in Cis than in Trans with Respect to CD3-TCR Stimulation","volume":"12","author":"Otano","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.immuni.2018.09.014","article-title":"Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-Tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function","volume":"49","author":"Buchan","year":"2018","journal-title":"Immunity"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"121","DOI":"10.36401\/JIPO-24-30","article-title":"4-1BB Antibodies in Oncology Clinical Trials: A Review","volume":"8","author":"Schwartz","year":"2025","journal-title":"J. Immunother. Precis. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/2326-6066.CIR-14-0007","article-title":"Targeting 4-1BB Costimulation to the Tumor Stroma with Bispecific Aptamer Conjugates Enhances the Therapeutic Index of Tumor Immunotherapy","volume":"2","author":"Schrand","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e970918","DOI":"10.4161\/21624011.2014.970918","article-title":"Reducing Toxicity of 4\u20131BB Costimulation: Targeting 4\u20131BB Ligands to the Tumor Stroma with Bi-Specific Aptamer Conjugates","volume":"4","author":"Schrand","year":"2015","journal-title":"OncoImmunology"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Wang, L., Liu, W.-Q., Broussy, S., Han, B., and Fang, H. (2023). Recent Advances of Anti-Angiogenic Inhibitors Targeting VEGF\/VEGFR Axis. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1307860"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1172\/JCI121266","article-title":"Osteopontin Mediates Glioblastoma-Associated Macrophage Infiltration and Is a Potential Therapeutic Target","volume":"129","author":"Wei","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"115140","DOI":"10.1016\/j.bios.2023.115140","article-title":"Multivalent Aptamer Nanoscaffold Cytosensor for Glioma Circulating Tumor Cells during Epithelial\u2013Mesenchymal Transition","volume":"226","author":"Wang","year":"2023","journal-title":"Biosens. Bioelectron."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1021\/acs.jmedchem.7b00527","article-title":"Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the Blood-Brain Barrier","volume":"60","author":"Monaco","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1039\/c3tb20815j","article-title":"Aptide-Conjugated Liposome Targeting Tumor-Associated Fibronectin for Glioma Therapy","volume":"1","author":"Saw","year":"2013","journal-title":"J. Mater. Chem. B"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"118870","DOI":"10.1016\/j.trac.2026.118870","article-title":"Structure-Guided Strategies for Aptamer Screening and Optimization: Advances and Perspectives","volume":"201","author":"Zhao","year":"2026","journal-title":"TrAC Trends Anal. Chem."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"109207","DOI":"10.1016\/j.compbiomed.2024.109207","article-title":"Wfold: A New Method for Predicting RNA Secondary Structure with Deep Learning","volume":"182","author":"Yuan","year":"2024","journal-title":"Comput. Biol. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1038\/s41467-025-60048-1","article-title":"Deep Generalizable Prediction of RNA Secondary Structure via Base Pair Motif Energy","volume":"16","author":"Zhu","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/s41592-024-02487-0","article-title":"Accurate RNA 3D Structure Prediction Using a Language Model-Based Deep Learning Approach","volume":"21","author":"Shen","year":"2024","journal-title":"Nat. Methods"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate Structure Prediction of Biomolecular Interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Chen, Z., Hu, L., Zhang, B.-T., Lu, A., Wang, Y., Yu, Y., and Zhang, G. (2021). Artificial Intelligence in Aptamer-Target Binding Prediction. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073605"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s43588-022-00249-6","article-title":"Generative Aptamer Discovery Using RaptGen","volume":"2","author":"Iwano","year":"2022","journal-title":"Nat. Comput. Sci."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s43588-024-00720-6","article-title":"Deep Generative Design of RNA Aptamers Using Structural Predictions","volume":"4","author":"Wong","year":"2024","journal-title":"Nat. Comput. Sci."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Jesky, R.G., Lo, L.H.Y., Siu, R.H.P., and Tanner, J.A. (2025). Designing the Future of Biosensing: Advances in Aptamer Discovery, Computational Modeling, and Diagnostic Applications. Biosensors, 15.","DOI":"10.3390\/bios15100637"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41746-026-02400-3","article-title":"Machine Learning Models for Drug-Drug Interaction Prediction from Computational Discovery to Clinical Application","volume":"9","author":"Lu","year":"2026","journal-title":"npj Digit. Med."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Richter, M., and Admasu, A. (2025). siRNA Features-Automated Machine Learning of 3D Molecular Fingerprints and Structures for Therapeutic Off-Target Data. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146795"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"15844","DOI":"10.1038\/s41598-024-66897-y","article-title":"Predicting Blood-Brain Barrier Permeability of Molecules with a Large Language Model and Machine Learning","volume":"14","author":"Huang","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"bbae517","DOI":"10.1093\/bib\/bbae517","article-title":"AptaDiff: De Novo Design and Optimization of Aptamers Based on Diffusion Models","volume":"25","author":"Wang","year":"2024","journal-title":"Brief. Bioinform."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1007\/s42452-025-08056-0","article-title":"Computational Approaches for Aptamer Research","volume":"7","author":"Jayawardena","year":"2025","journal-title":"Discov. Appl. Sci."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Golovin, A., Dzarieva, F., Rubetskaya, K., Shamadykova, D., Usachev, D., Pavlova, G., and Kopylov, A. (2025). In Silico Born Designed Anti-EGFR Aptamer Gol1 Has Anti-Proliferative Potential for Patient Glioblastoma Cells. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26031072"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Yang, L., Yin, Y., Liu, X., and Guo, B. (2026). Aptamer-Based Delivery of Genes and Drugs Across the Blood-Brain Barrier. Pharmaceuticals, 19.","DOI":"10.3390\/ph19010164"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1038\/s41598-021-85629-0","article-title":"AptaNet as a Deep Learning Approach for Aptamer-Protein Interaction Prediction","volume":"11","author":"Emami","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"gkaf1480","DOI":"10.1093\/nar\/gkaf1480","article-title":"RaptScore: A Large Language Model-Based Algorithm for Versatile Aptamer Evaluation","volume":"54","author":"Adachi","year":"2026","journal-title":"Nucleic Acids Res."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1021\/acssynbio.5c00196","article-title":"Direct Modeling of DNA and RNA Aptamers with AlphaFold 3: A Promising Tool for Predicting Aptamer Structures and Aptamer-Target Interactions","volume":"14","author":"Ochoa","year":"2025","journal-title":"ACS Synth. Biol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"bbaf616","DOI":"10.1093\/bib\/bbaf616","article-title":"A Comprehensive Benchmarking of the AlphaFold3 for Predicting Biomacromolecules and Their Interactions","volume":"26","author":"Peng","year":"2025","journal-title":"Brief. Bioinform."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Khairil, L., Benny, K.H.S., Jerry, J., Khatib, F.M., Che Ramli, M.D., and Kumar, S. (2026). AI in Drug Discovery: Clinical Failures, Regulatory Reality, and the Validation Crisis Behind the Hype. Pharmaceuticals, 19.","DOI":"10.3390\/ph19060916"},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"D\u2019Antonio, C., and Liguori, G.L. (2025). Modeling Glioblastoma for Translation: Strengths and Pitfalls of Preclinical Studies. Biology, 14.","DOI":"10.3390\/biology14111490"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"104179","DOI":"10.1016\/j.isci.2022.104179","article-title":"Algorithmic reconstruction of glioblastoma network complexity","volume":"25","author":"Uthamacumaran","year":"2022","journal-title":"iScience"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Uthamacumaran, A., and Zenil, H. (2022). A Review of Mathematical and Computational Methods in Cancer Dynamics. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.850731"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"bbag188","DOI":"10.1093\/bib\/bbag188","article-title":"Generative Design and Validation of Therapeutic Peptides for Glioblastoma Based on a Potential Target ATP5A","volume":"27","author":"Qian","year":"2026","journal-title":"Brief. Bioinform."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11060-015-1984-x","article-title":"ATP5A1 and ATP5B Are Highly Expressed in Glioblastoma Tumor Cells and Endothelial Cells of Microvascular Proliferation","volume":"126","author":"Xu","year":"2016","journal-title":"J. Neurooncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8231\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:28:33Z","timestamp":1789705713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":198,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188231"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188231","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}